Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/Carboplatin with or without Apatorsen in advanced squamous cell lung cancer
2014-000199-25Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Apr 2014
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apatorsen in Pulmonary squamous cell carcinoma (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Progression-free survival. Started Apr 2014; status: completed.
02
Drugs
apatorsen
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2014-000199-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000199-25.